Boston Scientific’s shares tumble 18% despite strong FY25 growth
Investors have seemingly homed in on flat sales in the Watchman and electrophysiology segments of Boston’s cardio portfolio, prompting a stock fall.
05 February 2026
05 February 2026
Investors have seemingly homed in on flat sales in the Watchman and electrophysiology segments of Boston’s cardio portfolio, prompting a stock fall.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.